Also, using a MSM, we then reexamined mortality risk of weekly ESA doses ≥30 000 versus <30 000 U/week (reference) in various subgroups: men versus women, age ≥65 versus <65 years, race/ethnicity (Caucasian versus African American versus Hispanic), diabetic versus nondiabetic, prior history versus no history of ischemic heart disease, body mass index ≥23 versus <23 kg/m2, and serum albumin level ≥3.8 versus <3.8 g/dL. This evidence concerns the gene ALB and coronary artery disorder.